TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) was the target of some unusual options trading on Monday. Stock investors bought 13,927 call options on the stock. This represents an increase of 105% compared to the average volume of 6,778 call options.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TGTX shares. The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. Finally, JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Up 14.4 %

Shares of TG Therapeutics stock opened at $34.42 on Tuesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $5.36 billion, a PE ratio of -344.17 and a beta of 2.26. TG Therapeutics has a 1-year low of $12.93 and a 1-year high of $36.84. The company’s fifty day simple moving average is $30.79 and its 200-day simple moving average is $28.24.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. As a group, equities analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TGTX. Arizona State Retirement System raised its stake in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock worth $1,283,000 after acquiring an additional 364 shares during the period. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company’s stock valued at $440,000 after purchasing an additional 463 shares during the period. Private Advisor Group LLC lifted its stake in shares of TG Therapeutics by 3.9% during the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 542 shares in the last quarter. Finally, Brookstone Capital Management boosted its holdings in TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 624 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.